Literature DB >> 7023662

Viruses and gynecologic cancers: herpesvirus protein (ICP 10/AG-4), a cervical tumor antigen that fulfills the criteria for a marker of carcinogenicity.

L Aurelian, I I Kessler, N B Rosenshein, G Barbour.   

Abstract

The studies associating infections by herpes simplex virus type 2 (HSV-2) with carcinoma of the human uterine cervix are reviewed within the context of three possible interpretations. Extensive seroepidemiologic evidence indicates that the virus does not grow preferentially in neoplastic tissue, nor is the association of HSV-2 with cervical carcinoma a reflection of their independent relationship to promiscuity. While a number of infectious agents, including other viruses, are associated with cervical atypia, only HSV-2 is a significant risk factor for CIS. In vitro transformation data supporting the oncogenic potential of the virus are summarized, and evidence is presented that an antigen designated ICP 10/AG-4 is a valid candidate for the role of a virus-encoded protein involved in the maintenance of a transformed phenotype. Antibody to AG-4 is IgM, and it is detected by microquantitative complement fixation. With this assay, it is demonstrated that conversion to anti-AG-4 occurs during primary infection with HSV-2; however, it is transient. In testing 1325 patients, a correlation was observed between antibody to AG-4 and cervical carcinoma. Thus, whereas only 11.7% of controls and 7.7% of patients with cancer at other sites are AG-4 seropositive, as many as 49.6% of patients with dysplasia, 63% of those with CIS, and 72.7% of those with invasive cancer are positive for the antibody. Antibody to AG-4 is related to tumor growth. This is evidence by 1) retrospective analyses demonstrating that the proportion of AG-4 seropositive individuals is directly correlated to the state of the disease and 2) prospective study of 209 patients demonstrating loss of antibody in patients with a successfully removed tumor mass and reappearance of AG-4 antibody in cancer recurrence. The possible use of AG-4 (or its antibody) in the diagnosis and monitoring of cervical carcinoma and its treatment is discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7023662     DOI: 10.1002/1097-0142(19810715)48:1+<455::aid-cncr2820481306>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Herpes simplex virus specifies two subunits of ribonucleotide reductase encoded by 3'-coterminal transcripts.

Authors:  M A Swain; D A Galloway
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

2.  Thymidine kinase-deficient herpes simplex virus type 2 genital infection in guinea pigs.

Authors:  L R Stanberry; S Kit; M G Myers
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

3.  Herpes simplex virus type 2 infection and cervical cancer: a prospective study of 12 years of follow-up in Finland.

Authors:  M Lehtinen; M Hakama; R K Aaran; A Aromaa; P Knekt; P Leinikki; J Maatela; R Peto; L Teppo
Journal:  Cancer Causes Control       Date:  1992-07       Impact factor: 2.506

4.  A research for the relationship between human papillomavirus and human uterine cervical carcinoma. I. The identification of viral genome and subgenomic sequences in biopsies of Chinese patients.

Authors:  J Y Si; K Lee; R Han; W Zhang; B B Tan; G X Song; S Liu; L F Chen; W M Zhao; L P Jia
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

5.  Invasive cervical cancer and depot-medroxyprogesterone acetate. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.

Authors:  D B Thomas; L Noonan; A Whitehead; D Roseman
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

6.  Invasive cervical cancer and combined oral contraceptives. WHO collaborative study of neoplasia and steroid contraceptives.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-30

7.  Quantitative cytospectrophotometric studies on protein thiols and reactive protein disulphides in samples of normal human uterine cervix and on samples obtained from patients with dysplasia or carcinoma-in-situ.

Authors:  G Nöhammer; F Bajardi; C Benedetto; E Schauenstein; T F Slater
Journal:  Br J Cancer       Date:  1986-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.